About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2021№5
Resolution of the Council of...

Resolution of the Council of Experts "Regulatory guidelines and issues relating to the organization of screening and prediction of preeclampsia in the Russian Federation"

DOI
https://dx.doi.org/10.18565/aig.2021.5.219-221
Full text (in Russian)

References

  1. Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S., Hall D.R., Warren C.E., Adoyi G., Ishaku S.; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018; 72(1): 24-43. https://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10803.
  2. Poon L.C., Shennan A., Hyett J.A., Kapur A., Hadar E. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019; 145(Suppl 1): 1-33. https://dx.doi.org/10.1002/ijgo.12802.
  3. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. 2018. [Key performance indicators of the Maternal and Child Health Service in the Russian Federation. 2018. (in Russian].
  4. Turbeville H.R., Sasser J.M. Preeclampsia beyond pregnancy: long-term consequences for mother and child. Am J Physiol Renal Physiol. 2020; 318(6): F1315-F1326. https://dx.doi.org/10.1152/ajprenal.00071.2020.
  5. Wu P., Haththotuwa R., Kwok C.S., Babu A., Kotronias R.A., Rushton C., Zaman A., Fryer A.A., Kadam U., Chew-Graham C.A., Mamas M.A. Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2017; 10(2): e003497. https://dx.doi.org/10.1161/CIRCOUTCOMES.116.003497.
  6. Ходжаева З.С., Холин А.М., Вихляева Е.М. Ранняя и поздняя преэклампсия: парадигмы патобиологии и клиническая практика. Акушерство и гинекология. 2013; 10: 4-11. [Khodzhaeva Z.S., Kholin A.M., Vikhlyaeva E.M. Early and late preeclampsia: Pathobiology paradigms and clinical practice. Obstetrics and Gynecology. 2013; 10: 4-11. (in Russian)].
  7. Khodzhaeva Z.S., Kogan Ye.A., Shmakov R.G., Klimenchenko N.I., Akatyeva A.S., Vavina O.V., Kholin A.M., Muminova K.T., Sukhikh G.T. Clinical and pathogenetic features of early- and late-onset pre-eclampsia. J Matern Fetal Neonatal Med. 2016; 29(18): 2980-6. https://dx.doi.org/10.3109/14767058.2015.1111332.
  8. Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013; 209(6): 544.e1-544.e12. https://dx.doi.org/10.1016/j.ajog.2013.08.019.
  9. Ташкина Е. А., Черных Е.Р., Пасман Н.М. Роль ангиогенных факторов и их взаимодействия с иммунной системой при неосложненной беременности и преэклампсии. Национальный конгресс «Дискуссионные вопросы современного акушерства» 15–17 июня 2017 г. Журнал акушерства и женских болезней. 2017: 79. [Tashkina E.A., Chernykh E.R., Pasman N.M. The role of angiogenic factors and their interaction with the immune system in uncomplicated pregnancy and preeclampsia. National Congress "Debating Issues of Modern Obstetrics" June 15–17, 2017. Journal of Obstetrics and Women's Diseases. 2017: 79. (in Russian)].
  10. Uzan J., Carbonnel M., Piconne O., Asmar R. Pre-eclampsia: Pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011; 7(1): 467-74. https://dx.doi.org/10.2147/VHRM.S20181.
  11. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013; 33(1): 8-15. doi: 10.1159/000341264.
  12. Ходжаева З.С., Холин А.М., Шувалова М.П., Иванец Т.Ю., Демура С.А., Галичкина И.В. Российская модель оценки эффективности теста на преэклампсию sFlt-1/PlGF. Акушерство и гинекология. 2019; 2: 52-8. [Khodzhaeva Z.S., Kholin A.M., Shuvalova M.P., Ivanets T.Yu., Demura S.A., Galichkina I.V. A Russian model for evaluating the efficiency of the sFlt-1/PlGF test for preeclampsia. Obstetrics and Gynecology. 2019; 2: 52-8 (in Russian]. https://dx.doi.org/10.18565/aig.2019.2.52-58.
  13. Kenny L.C., Black M.A., Poston L., Taylor R., Myers J.E., Baker P.N., et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertens. 2014; 64(3): 644-52. https://dx.doi.org/10.1161/HYPERTENSIONAHA.
  14. O’Gorman N., Wright D., Syngelaki A., Akolekar R., Wright A., Poon L.C., et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016; 214(1): 103.e1-103.e12. https://dx.doi.org/10.1016/j.ajog.2015.08.034.
  15. O’Gorman N., Wright D., Poon L.C., Rolnik D.L., Syngelaki A., Wright A., et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017; 49(6): 751-5. https://dx.doi.org/10.1002/uog.17399.
  16. Zhong Y., Zhu F., Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2015; 15:191. https://dx.doi.org/10.1186/s12884-015-0608-y.
  17. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M. et al. Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1): 13-22. https://dx.doi.org/10.1056/NEJMoa1414838.
  18. Hadker N., Garg S., Costanzo C., van der Helm W., Creeden J. Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective/ Hypertens Pregnancy, 2013; 32(2): 105-19. http://dx.doi.org/10.3109/10641955.2011.638958.
  19. Nielsen L.H., Sundtoft I., Vestgaard M.J., Persson L., Storgaard L., Salvig J.D. et al. Hypertension og præeklampsi. Indholdsfortegnelse. 2018.
  20. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J., et al. Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation. 2012; 125(7): 911-9. https://dx.doi.org/10.1161/CIRCULATIONAHA.111.054361.
  21. Poon L.C., Galindo A., Surbek D., Chantraine F., Stepan H., Hyett J., Tan K.H., Verlohren S. From first-trimester screening to risk stratification of evolving pre-eclampsia in the second and third trimesters of pregnancy: a comprehensive approach. Ultrasound Obstet Gynecol. 2020; 55(1): 5-12. https://dx.doi.org/10.1002/uog.21869.
  22. Stepan H., Hund M., Dilba P., Sillman J., Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin Chem Lab Med. 2019; 57(9): 1339-48. http://dx.doi.org/10.1515/cclm-2018-1228.
  23. Perdigao J.L, Chinthala S., Mueller A., Minhas R., Ramadan H., Nasim R. et al. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. Hypertension. 2019; 73(4): 868-77. https://dx.doi.org/10.1161/HYPERTENSIONAHA.118.12205.
  24. Dröge L.A., Höller A., Ehrlich L., Verlohren S., Henrich W., Perschel F.H. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®. Pregnancy Hypertens. 2017; 8: 31-6. https://dx.doi.org/10.1016/j.preghy.2017.02.005.
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.